The TNBC market is projected to expand, driven by rising disease prevalence, advances in targeted treatment options, and the introduction of new therapies, including DATROWAY [(Datopotamab Deruxtecan), AstraZeneca and Daiichi Sankyo], IMFINZI [(Durvalumab), AstraZeneca], PADCEV [(Enfortumab vedotin), Astellas Pharma and Pfizer], Tilarginine [(L-NMMA), Galera Therapeutics], and others.
DelveInsight’s Triple-Negative Breast Cancer Market Insights report includes a comprehensive understanding of current treatment practices, triple-negative breast cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Triple-Negative Breast Cancer Market Summary
- The triple-negative breast cancer market across the 7MM reached an estimated USD 4.5 billion in 2024. The United States dominated this landscape, representing about 69% of the total market value, far surpassing the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- KEYTRUDA (pembrolizumab), together with chemotherapy, remained the most widely used treatment option, accounting for roughly USD 2 billion in combined revenue across the 7MM in 2024. That same year, the region reported around 104,000 new TNBC diagnoses. With an anticipated CAGR of 0.7%, incidence is expected to rise steadily, contributing to a growing disease burden by 2034.
- Several major companies, including AstraZeneca, Daiichi Sankyo, Astellas Pharma, Pfizer, Galera Therapeutics, BioNTech, and others, are advancing next-generation TNBC therapies.
- Notable TNBC drugs in the clinical trials include DATROWAY (Datopotamab Deruxtecan), PADCEV (Enfortumab Vedotin), Tilarginine, BNT327/PM8002, IMFINZI (Durvalumab), and others poised to enter the market in the coming years.
Discover the TNBC new treatment @ New Treatments for TNBC
What is Triple-Negative Breast Cancer?
Triple-negative breast cancer is a particularly aggressive and diverse form of breast cancer that lacks expression of estrogen receptors (ER), progesterone receptors (PR), and HER2. It accounts for a substantial share of breast cancer cases and is associated with fast disease progression, high chances of recurrence, and unfavorable outcomes. TNBC tends to occur more frequently in younger women, individuals of African American descent, and those with BRCA1 gene mutations.
Triple-Negative Breast Cancer Epidemiology Segmentation
The triple-negative breast cancer epidemiology section provides insights into the historical and current triple-negative breast cancer patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The triple-negative breast cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:
- Total Incident Cases of Breast Cancer
- Total Incident Cases of TNBC
- Gene Mutation-specific Incident Cases of TNBC
- Stage-specific Incident Cases of TNBC
- Age-specific Incident Cases of TNBC
- Line-wise Treated Incident Cases of TNBC
Triple-Negative Breast Cancer Market Analysis
TNBC does not express hormone receptors or HER2, making it unresponsive to endocrine therapy or HER2-targeted treatments. As a result, systemic chemotherapy has traditionally been the primary therapeutic approach, particularly for metastatic disease. Care typically begins with neoadjuvant or adjuvant chemotherapy and advances to first-line regimens in later stages. When the cancer progresses or responds poorly, subsequent lines of therapy are introduced. Immunotherapies, especially PD-1/PD-L1 inhibitors, are increasingly used in metastatic TNBC to strengthen immune-mediated tumor control.
In early-stage TNBC, the PD-1 inhibitor KEYTRUDA (pembrolizumab) is now a standard option, given in combination with neoadjuvant chemotherapy and continued as adjuvant monotherapy. For PD-L1–positive patients (CPS ≥10), it is also administered with chemotherapy in patients with locally recurrent or metastatic disease. Precision therapies are also gaining ground, particularly in patients with BRCA mutations; PARP inhibitors such as LYNPARZA (olaparib) and TALZENNA (talazoparib) exploit defects in DNA repair pathways. TRODELVY (sacituzumab govitecan), a TROP-2–targeting antibody-drug conjugate, is approved for metastatic TNBC that has relapsed or become resistant to prior therapies. Although TECENTRIQ (atezolizumab) was withdrawn in the U.S. after unsuccessful confirmatory trials, it remains accessible in Europe and Japan.
Taxane-based chemotherapy remains a key component of TNBC management and is frequently paired with immune checkpoint inhibitors in PD-L1–positive disease. While platinum-based agents are sometimes used, their clinical benefits have been inconsistent and accompanied by toxicity concerns. Despite these advancements, TNBC remains an aggressive cancer subtype, emphasizing the ongoing need for therapeutic breakthroughs.
Overall, existing treatment options often fail to provide durable control, underscoring the critical need for innovative therapies that can significantly improve long-term outcomes and survival in TNBC.
To know more about FDA-approved drugs for TNBC, visit @ Approved TNBC Treatment
Key Factors Driving the Growth of the Triple-Negative Breast Cancer Market
Rising TNBC Incidence & Prevalence
TNBC accounts for about 15–20% of all breast cancer cases worldwide. In the US, the incident cases are expected to rise at a CAGR of 1% by 2034.
Advances in Targeted & Immunotherapies
The emergence of checkpoint inhibitors (e.g., anti–PD-1/PD-L1), PARP inhibitors, ADCs, and other precision therapies is expanding treatment options and improving outcomes.
High Unmet Need in TNBC Market
TNBC lacks expression of ER, PR, and HER2, making it unresponsive to conventional targeted and hormonal therapies. This creates a significant demand for novel treatment options.
Emergence of TNBC Drugs
There is a significant need for new treatments for TNBC, as current therapies often fail to manage the disease entirely. Innovative drug development could offer more effective options, improving outcomes for patients with this aggressive cancer. Several promising TNBC drugs are currently in clinical trials, including DATROWAY (AstraZeneca/Daiichi Sankyo), Adagloxad Simolenin (OBI Pharma), PADCEV (Astellas Pharma/Pfizer), BNT327/PM8002 (BioNTech), and Tilarginine (Galera Therapeutics), among others.
Triple-Negative Breast Cancer Competitive Landscape
Several investigational therapies are progressing through the triple-negative breast cancer (TNBC) pipeline, including DATROWAY (datopotamab deruxtecan; AstraZeneca/Daiichi Sankyo), IMFINZI (durvalumab; AstraZeneca), PADCEV (enfortumab vedotin; Astellas Pharma/Pfizer), Tilarginine (L-NMMA; Galera Therapeutics), and others.
AstraZeneca/Daiichi Sankyo’s Dato-DXd, marketed as DATROWAY, is an experimental antibody–drug conjugate (ADC) under evaluation for TNBC—both as a monotherapy and in combination with IMFINZI (durvalumab). Targeting high-risk patients, including those with PD-L1–positive disease, the therapy is advancing through pivotal Phase III trials, with initial results expected in 2025 and more extensive findings anticipated in 2026. These outcomes could play a key role in shaping future TNBC treatment strategies.
AstraZeneca and Daiichi Sankyo jointly develop part of a global development alliance formed in July 2020, Dato-DXd. Daiichi Sankyo maintains exclusive rights in Japan and is responsible for manufacturing and supply, while both partners co-lead development across multiple tumor types worldwide.
Galera Therapeutics’ Tilarginine (L-NMMA), a broad nitric oxide synthase (NOS) inhibitor, is currently in Phase II trials for metaplastic breast cancer (MpBC) in combination with alpelisib and nab-paclitaxel in HER2-negative metastatic or locally advanced disease. It is also being assessed with a taxane in Phase II studies for metastatic or locally advanced TNBC. In December 2024, Galera Therapeutics acquired Nova Pharmaceuticals, further supporting its development efforts.
AstraZeneca’s IMFINZI (durvalumab), an FDA-approved PD-L1 inhibitor, enhances immune recognition of tumor cells by blocking PD-L1 signaling. It is being evaluated in Phase I/II trials with paclitaxel and other innovative agents as a first-line therapy for metastatic TNBC, with key data expected toward the end of 2025. The BEGONIA study (October 2023) demonstrated robust and sustained tumor responses, and a favorable safety profile, for the combination of datopotamab deruxtecan and IMFINZI as a first-line option for mTNBC.
As these advanced therapies progress toward approval, they are expected to significantly reshape the TNBC treatment landscape, establishing new standards of care and opening pathways for future innovation and market growth.
Discover more about triple-negative breast cancer drugs in development @ Triple-Negative Breast Cancer Clinical Trials
Recent Developments in the Triple-Negative Breast Cancer Market
- In May 2025, Gilead Sciences, Inc. announced that combining TRODELVY (sacituzumab govitecan-hziy) with KEYTRUDA (pembrolizumab) reduced the risk of disease progression or death by 35% (hazard ratio: 0.65) compared with the standard regimen of Keytruda plus chemotherapy as a first-line treatment for patients with PD-L1–positive (CPS ≥10) metastatic triple-negative breast cancer (TNBC).
- In May 2025, Gilead also reported positive topline findings from the Phase 3 ASCENT-03 trial of TRODELVY. The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) over chemotherapy in first-line mTNBC patients who are ineligible for PD-1/PD-L1 inhibitors, either because they are PD-L1 negative or otherwise unable to receive immunotherapy.
| Triple-Negative Breast Cancer Market Report Metrics | Details |
| Study Period | 2020–2034 |
| Coverage | 7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. |
| Triple-Negative Breast Cancer Market CAGR | 4.7% |
| Triple-Negative Breast Cancer Market Size in 2024 | USD 4.5 Billion |
| Key Triple-Negative Breast Cancer Companies | AstraZeneca, Daiichi Sankyo, Astellas Pharma, Pfizer, Galera Therapeutics, BioNTech, Merck, Gilead Sciences, Roche, Genentech, and others |
| Key Triple-Negative Breast Cancer Therapies | DATROWAY (Datopotamab Deruxtecan), PADCEV (Enfortumab vedotin), Tilarginine, BNT327/PM8002, IMFINZI (Durvalumab), KEYTRUDA, TRODELVY, TALZENNA, LYNPARZA, TECENTRIQ, and others |
Scope of the Triple-Negative Breast Cancer Market Report
- Therapeutic Assessment: Triple-Negative Breast Cancer current marketed and emerging therapies
- Triple-Negative Breast Cancer Market Dynamics: Key Market Forecast Assumptions of Emerging Triple-Negative Breast Cancer Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Triple-Negative Breast Cancer Market Access and Reimbursement
Download the report to understand which factors are driving triple-negative breast cancer market trends @ Triple-Negative Breast Cancer Market Forecast
Table of Contents
| 1 | Key Insights |
| 2 | Report Introduction |
| 3 | TNBC Market Overview at a Glance |
| 3.1 | Market Share (%) Distribution of TNBC by Therapies in the 7MM in 2020 |
| 3.2 | Market Share (%) Distribution of TNBC by Therapies in the 7MM in 2034 |
| 4 | Executive Summary |
| 5 | Key Events |
| 6 | Disease Background and Overview |
| 6.1 | Introduction |
| 6.2 | Various Subtypes of Breast Cancer Based on Immunohistochemical Expression |
| 6.3 | TNBC Overview |
| 6.4 | Diagnosis |
| 6.5 | Treatment and Management |
| 7 | Epidemiology and Market Forecast Methodology |
| 8 | Epidemiology and Patient Population |
| 8.1 | Key Findings |
| 8.2 | Assumptions and Rationale: 7MM |
| 8.2.1 | Incident Cases of Breast Cancer |
| 8.2.2 | Incident Cases of TNBC |
| 8.2.3 | Gene Mutation-specific Incident Cases of TNBC |
| 8.2.4 | Stage-specific Incident Cases of TNBC |
| 8.2.5 | Age-specific Incident Cases of TNBC |
| 8.3 | Total Incident Cases of Breast Cancer in the 7MM |
| 8.4 | Total Incident Cases of TNBC in the 7MM |
| 8.5 | The United States |
| 8.6 | EU4 and the UK |
| 8.7 | Japan |
| 9 | Patient Journey |
| 10 | Marketed Therapies |
| 10.1 | Key Cross Competition |
| 10.2 | KEYTRUDA (pembrolizumab): Merck |
| 10.2.1 | Product Description |
| 10.2.2 | Regulatory Milestone |
| 10.2.3 | Other Developmental Activities |
| 10.2.4 | Clinical Trials Information |
| 10.2.5 | Safety and Efficacy |
| 10.3 | TRODELVY (sacitzumab govitecan-hziy): Gilead Sciences |
| 10.4 | TALZENNA (talazoparib): Pfizer |
| 10.5 | LYNPARZA (olaparib): AstraZeneca/Merck |
| 10.6 | TECENTRIQ (atezolizumab): Roche/Genentech |
| To be continued in the report… | |
| 11 | Emerging Drug Profiles |
| 11.1 | Key Cross Competition of Emerging Drugs |
| 11.2 | DATROWAY (Datopotamab Deruxtecan): AstraZeneca/Daiichi Sankyo |
| 11.2.1 | Drug Description |
| 11.2.2 | Other Developmental Activities |
| 11.2.3 | Clinical Trials Information |
| 11.2.4 | Safety and Efficacy |
| 11.2.5 | Analysts’ View |
| 11.3 | PADCEV (Enfortumab vedotin): Astellas Pharma/Pfizer |
| 11.4 | Tilarginine: Galera Therapeutics |
| 11.5 | BNT327/PM8002: BioNTech |
| 11.6 | IMFINZI (Durvalumab): AstraZeneca |
| To be continued in the report… | |
| 12 | TNBC: Market Analysis |
| 12.1 | Key Findings |
| 12.2 | TNBC Market Outlook |
| 12.3 | Attribute Analysis |
| 12.4 | Key Market Forecast Assumptions |
| 12.5 | Total Market Size of TNBC in the 7MM |
| 12.6 | Market Size of TNBC by Therapies in the 7MM |
| 12.7 | Market Size of TNBC in the United States |
| 12.8 | Market Size of TNBC in EU4 and the UK |
| 12.9 | Market Size of TNBC in Japan |
| 13 | Key Opinion Leaders’ Views |
| 14 | Unmet Needs |
| 15 | SWOT Analysis |
| 16 | Market Access and Reimbursement |
| 16.1 | The United States |
| 16.2 | In EU4 and the UK |
| 16.3 | Japan |
| 17 | Acronyms and Abbreviations |
| 18 | Bibliography |
| 19 | TNBC Market Report Methodology |
Related Reports
PD-L1 Inhibitors Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PD-L1 inhibitors companies including EQRX, CSTONE PHARMACEUTICALS, PFIZER, NOVARTIS, ARCUS BIOSCIENCES, AGENUS, TRACON PHARMACEUTICALS, SHANGHAI HENLIUS BIOTECH, INCYTE CORPORATION, among others.
PARP Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PARP inhibitors companies including AstraZeneca, Merck, Janssen, Pfizer, Astellas, Pharma& Schweiz, AtlasMedx, AbbVie, GlaxoSmithKline, Pfizer, BeiGene, Allarity Therapeutics, among others.
Triple-Negative Breast Cancer Clinical Trial Analysis
Triple-Negative Breast Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key TNBC companies, including G1 Therapeutics, Inc., Gilead Sciences, Biotheus Inc., GlaxoSmithKline, AstraZeneca, Shanghai Jiaolian Drug Research and Development Co., Ltd, Coherent Biopharma, Daiichi Sankyo Company, Merck, SynDevRx, Inc., Treadwell Therapeutics, AstraZeneca, Novartis Pharmaceuticals, NEC Corporation, Cardiff Oncology, Ocellaris Pharma, Inc., Nuvation Bio Inc., Phoenix Molecular Designs, Pure Biologics S.A., Pure Biologics S.A., Mersana Therapeutics, Zumutor Biologics Inc., Tubulis GmbH, Hinova Pharmaceuticals, Primevax, ARCE Therapeutics, HC Biopharma, Casinvent, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
